Ewing's Family of Tumors disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: EWN002 MIFTS: 45	Ewing's Family of Tumors malady Categories: Genetic diseases, Rare diseases, Neuronal diseases, Bone diseases
Genes Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Aliases & Classifications for Ewing's Family of Tumors

Sources:
⁴⁸NIH Rare Diseases, ⁶⁸UMLS
See all MalaCards sources

Aliases & Descriptions for Ewing's Family of Tumors:

Name: Ewing's Family of Tumors ⁴⁸

Neuroectodermal Tumor, Primitive ⁶⁸

Primitive Neuroectodermal Tumor ⁴⁸

Ewing’s Tumor of Bone ⁴⁸

Extraosseous Ewing’s ⁴⁸

Ewing Family of Tumors ⁴⁸

Askin’s Tumor ⁴⁸

Classifications:

MalaCards categories:
Global: Genetic diseases, Rare diseases
Anatomical: Neuronal diseases, Bone diseases

See all MalaCards categories (disease lists)

Summaries for Ewing's Family of Tumors

Sources:
³⁶MalaCards
See all MalaCards sources

MalaCards based summary: Ewing's Family of Tumors, also known as neuroectodermal tumor, primitive, is related to extraosseous ewing's sarcoma and askin's tumor. An important gene associated with Ewing's Family of Tumors is EWSR1 (EWS RNA Binding Protein 1), and among its related pathways are Regulation of KIT signaling and Tyrosine Kinases / Adaptors. Affiliated tissues include bone, nk cells and lung, and related mouse phenotypes are Increased shRNA abundance (Z-score > 2) and Increased transferrin (TF) endocytosis.

Related Diseases for Ewing's Family of Tumors

Sources:
²⁰GeneAnalytics, ²¹GeneCards
See all MalaCards sources

Diseases related to Ewing's Family of Tumors via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 110)

id	Related Disease	Score	Top Affiliating Genes
1	extraosseous ewing's sarcoma	12.4
2	askin's tumor	12.4
3	supratentorial primitive neuroectodermal tumor	12.4
4	cerebral primitive neuroectodermal tumor	12.3
5	intracranial primitive neuroectodermal tumor	12.2
6	extraosseous ewings sarcoma-primitive neuroepithelial tumor	11.2
7	ewing sarcoma	11.1
8	sarcoma	10.7
9	congenital cystic eye multiple ocular and intracranial anomalies	10.6	FLI1, MTOR
10	filamentary keratitis	10.5	KIT, KITLG
11	corneal granular dystrophy	10.5	KIT, KITLG
12	myotonic dystrophy 1	10.5	EPO, KITLG
13	animal phobia	10.5	ERBB2, KIT
14	internal auditory canal meningioma	10.5	EPO, EWSR1
15	diffuse cutaneous mastocytosis	10.5	KIT, KITLG
16	pericoronitis	10.5	KIT, KITLG
17	vaginal adenosarcoma	10.5	ERBB2, KIT
18	movement disease	10.5	KIT, KITLG
19	focal chorioretinitis	10.4	ERBB2, KIT
20	autosomal recessive non-syndromic intellectual disability	10.4	KIT, KITLG
21	breast papillary carcinoma	10.4	ERBB2, KIT
22	cholesteatoma of external ear	10.4	ERBB2, KIT
23	malignant gastric teratoma	10.3	CDKN2A, MTOR
24	stress polycythemia	10.3	EPO, EPOR
25	mastroiacovo de rosa satta syndrome	10.3	KIT, KITLG
26	methemoglobinemia	10.3	EPO, EPOR
27	anomalous left coronary artery from the pulmonary artery	10.3	ERBB2, MTOR
28	juxtacortical chondrosarcoma	10.3	CDKN2B, EWSR1
29	vulvar sebaceous carcinoma	10.3	CDK4, EWSR1, KIT
30	dic in newborn	10.3	EPO, EPOR
31	skeletal tuberculosis	10.3	CDKN2A, ERBB2
32	placental choriocarcinoma	10.3	CDK4, EWSR1, KIT
33	clear cell sarcoma	10.3	CDK4, EWSR1, KIT
34	ataxias and cerebellar or spinocerebellar degeneration	10.3	EPO, FAS
35	extragonadal seminoma	10.3	CDKN2A, ERBB2
36	angora hair nevus	10.3	EWSR1, FLI1
37	karak syndrome	10.3	CDK4, CDKN2A
38	epidural spinal canal angiolipoma	10.3	CDK4, CDKN2A
39	megarbane jalkh syndrome	10.3	CSF3, EWSR1, FLI1
40	cutaneous solitary mastocytoma	10.3	KIT, KITLG
41	oral pharyngeal disorders	10.3	CDKN2A, ERBB2
42	heel spur	10.3	CDKN2A, ERBB2
43	vulva squamous cell carcinoma	10.2	CDKN2A, ERBB2
44	erythrocytosis, familial, 2	10.2	EPO, EPOR
45	white platelet syndrome	10.2	CDKN2A, MTOR
46	infiltrative basal cell carcinoma	10.2	CDKN2A, KIT
47	pleuropulmonary blastoma type 2	10.2	CDK4, CDKN2A
48	hypersplenism	10.2	CDKN2A, KIT
49	drachtman weinblatt sitarz syndrome	10.1	CSF3, EPOR
50	vulvar liposarcoma	10.1	CDK4, KIT

Graphical network of the top 20 diseases related to Ewing's Family of Tumors:

Symptoms & Phenotypes for Ewing's Family of Tumors

Sources:
²⁶GenomeRNAi, ⁴¹MGI
See all MalaCards sources

GenomeRNAi Phenotypes related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

²⁶

id	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-35	9.2	CDK4, EWSR1, KIT, MTOR
2	Increased transferrin (TF) endocytosis	GR00363-A	7.0	CDK4, CDKN2A, CDKN2B, EPO, EPOR, ERBB2

MGI Mouse Phenotypes related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

⁴¹ (show all 22)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	pigmentation	MP:0001186	8.2	CDK4, CDKN2A, FAS, KIT, KITLG, RB1
2	skeleton	MP:0005390	7.9	CDKN2A, ERBB2, FAS, KIT, KITLG, MTOR
3	no phenotypic analysis	MP:0003012	7.9	CDKN2A, CDKN2B, EPOR, KIT, MTOR, RB1
4	digestive/alimentary	MP:0005381	7.7	CDK4, CDKN2A, ERBB2, FAS, KIT, KITLG
5	normal	MP:0002873	7.6	CDK4, EPO, EPOR, ERBB2, FAS, KIT
6	renal/urinary system	MP:0005367	7.5	CDK4, CDKN2B, CSF3, FAS, KIT, MTOR
7	muscle	MP:0005369	7.5	CDK4, CDKN2A, EPO, ERBB2, FLI1, KIT
8	reproductive system	MP:0005389	7.4	CDK4, CDKN2A, CDKN2B, ERBB2, FAS, KIT
9	respiratory system	MP:0005388	7.4	CDKN2A, EPO, EPOR, ERBB2, FAS, KIT
10	neoplasm	MP:0002006	7.1	CDK4, CDKN2A, CDKN2B, ERBB2, FAS, FLI1
11	liver/biliary system	MP:0005370	7.1	CDK4, CDKN2A, EPO, EPOR, FAS, FLI1
12	embryo	MP:0005380	6.8	CDK4, CDKN2A, EPO, EPOR, ERBB2, FLI1
13	endocrine/exocrine gland	MP:0005379	6.8	CDK4, CDKN2A, CDKN2B, ERBB2, FAS, FLI1
14	growth/size/body region	MP:0005378	6.8	CDK4, CDKN2A, EPOR, ERBB2, FAS, FLI1
15	nervous system	MP:0003631	6.8	CDK4, CDKN2A, EPOR, ERBB2, FAS, FLI1
16	cardiovascular system	MP:0005385	6.6	CDK4, CDKN2A, EPO, EPOR, ERBB2, FAS
17	integument	MP:0010771	6.3	CDK4, CDKN2A, CDKN2B, CSF3, EPO, ERBB2
18	homeostasis/metabolism	MP:0005376	6.0	CDK4, CDKN2A, CDKN2B, EPO, EPOR, ERBB2
19	cellular	MP:0005384	5.9	CDK4, CDKN2A, CDKN2B, EPO, EPOR, ERBB2
20	mortality/aging	MP:0010768	5.8	CDK4, CDKN2A, CDKN2B, EPO, EPOR, ERBB2
21	immune system	MP:0005387	5.7	CDK4, CDKN2A, CDKN2B, CSF3, EPO, EPOR
22	hematopoietic system	MP:0005397	5.7	CDK4, CDKN2A, CDKN2B, CSF3, EPO, EPOR

Drugs & Therapeutics for Ewing's Family of Tumors

Sources:
¹BitterDB, ⁴ClinicalTrials, ¹⁰DGIdb, ¹⁴DrugBank, ²⁹HMDB, ³³IUPHAR, ⁵⁰Novoseek, ⁵⁶PharmGKB
See all MalaCards sources

Drugs for Ewing's Family of Tumors (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 301)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dolutegravir

approved

Phase 4

141

1051375-16-6

54726191

Darunavir

approved

Phase 4

205

635728-49-3, 206361-99-1

213039

Synonyms:

(3-((4-aminobenzenesulfonyl)isobutylamino)-1-benzyl-2-hydroxypropyl)carbamic acid hexahydrofuro(2,3-b)furan-3-yl ester

(3R,3AS,6AR)-HEXAHYDROFURO[2,3-B]FURAN-3-YL(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](ISOBUTYL)AMINO]-1-BENZYL-2-HYDROXYPROPYLCARBAMATE

(3R,3AS,6ar)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate

(3R,3AS,6ar)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate

(3R,3AS,6ar)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate

(3R,3AS,6ar)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate

(3R,3aS,6aR)-Hexahydrofuro(2,3-b)furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N1-isobutylsulfanilamido)propyl)carbamate

(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl N-((1S,2R)-1-benzyl-2-hydroxy-3-(N(1)-isobutylsulfanilamido)propyl)carbamate

(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate

(3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-isobutylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate

(3R,3aS,6aR)-tetrahydro-2H-furo[2,3-b]furan-3-yl (2S,3R)-4-(4-amino-N-neopentylphenylsulfonamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate

206361-99-1

2f80

2f81

2f8g

2hs1

2hs2

2idw

2ien

3bvb

3cyw

3d1z

3d20

618109-00-5

AC1L4U4V

AIDS073035

CHEBI:367163

CHEMBL1323

CID213039

Carbamic acid, [(1S,2R)-3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-, (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl ester

D03656

DB01264

Darunavir

Darunavir (USAN/INN)

Darunavir [USAN]

Darunavirum

Darunavirum [INN-Latin]

Darunavirum [INN-latin]

LS-187026

LS-187772

LS-191295

MolPort-003-846-141

N-((1S,2R)-3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-benzylpropyl)((1S,2R,5R)-4,6-dioxabicyclo(3.3.0)oct-2-yloxy)carboxamide

Prezista

Prezista(TM)

TMC 114

TMC-114

TMC114

UIC 94017

UIC-94017

UIC-96017

UNII-YO603Y8113

[(3aS,4R,6aR)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] N-[(2S,3R)-4-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate

[(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester

[(S)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-2-hydroxy-1-((R)-phenylmethyl)-propyl]-carbamic acid (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester

{(1S,2R)-3-[(4-Amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3aS,6aR)-(hexahydro-furo[2,3-b]furan-3-yl) ester

{(1S,2R)-3-[(4-amino-benzenesulfonyl)-isobutyl-amino]-1-benzyl-2-hydroxy-propyl}-carbamic acid (3R,3as,6ar)-(hexahydro-furo[2,3-b]furan-3-yl) ester

Ritonavir

approved, investigational

Phase 4

870

155213-67-5

392622

Synonyms:

1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate

155213-67-5

1hxw

1sh9

5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate

5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate

538, ABT

A-84538

ABBOTT-84538

ABT 538

ABT 84538

ABT-538

ABT538

AC-733

AC1L94GB

AKOS000280930

Abbott 84538

BIDD:GT0387

BIDD:PXR0023

Bio-0093

C07240

C37H48N6O5S2

CHEBI:45409

CHEMBL163

CID392622

CPD000466395

D00427

D019438

DB00503

DRG-0244

FT-0082824

HMS2051B08

HSDB 7160

LS-148860

MLS000759541

MLS001424063

MolPort-000-883-877

N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide

NCGC00159462-02

NSC693184

Norvir

Norvir (TM)

Norvir (TN)

Norvir Sec

RIT

RTV

Ritonavir

Ritonavir (JAN/USAN/INN)

Ritonavir [USAN]

Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.

Ritonavirum

S1185_Selleck

SAM001246783

SMR000466395

STK634209

ZINC03944422

ritonavir

Anti-Infective Agents

Phase 4, Phase 3, Phase 2, Phase 1

21402

Anti-Retroviral Agents

Phase 4, Phase 2, Phase 1

3232

Anti-HIV Agents

Phase 4, Phase 2, Phase 1

3100

Antiviral Agents

Phase 4, Phase 2, Phase 1

9732

protease inhibitors

Phase 4, Phase 2

5320

Synonyms:

protease inhibitors

HIV Protease Inhibitors

Phase 4, Phase 2

5319

Integrase Inhibitors

Phase 4

408

Cytochrome P-450 CYP3A Inhibitors

Phase 4

1666

Cytochrome P-450 Enzyme Inhibitors

Phase 4

3822

HIV Integrase Inhibitors

Phase 4

387

Mesna

approved

Phase 3, Phase 1, Phase 2

258

19767-45-4, 3375-50-6

598

Synonyms:

2-Mercaptoethanesulfonate

2-Mercaptoethanesulfonic acid

2-mercaptoethane sulfonate Na

CoM

Coenzyme M

HS-CoM

Cyclophosphamide

approved, investigational

Phase 3, Phase 1, Phase 2

2829

50-18-0, 6055-19-2

2907

Synonyms:

(+-)-Cyclophosphamide

(-)-Cyclophosphamide

(RS)-Cyclophosphamide

1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine

1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin

2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide

4-Hydroxy-cyclophosphan-mamophosphatide

50-18-0

60007-95-6

6055-19-2 (monohydrate)

75526-90-8

AC1L1EQQ

AI3-26198

ASTA

ASTA B518

Anhydrous cyclophosphamide

Asta B 518

B 518

B-518

BRN 0011744

BSPBio_002099

Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester

C 0768

C07888

C7H15Cl2N2O2P

CB 4564

CB-4564

CCRIS 188

CHEBI:4027

CHEMBL32520

CHEMBL88

CID2907

CPA

CTX

Ciclofosfamida

Ciclofosfamida [INN-Spanish]

Ciclofosfamide

Ciclophosphamide

Ciclophosphamide [INN]

Clafen

Claphene

Cycloblastin

Cyclophosphamid

Cyclophosphamide

Cyclophosphamide (INN)

Cyclophosphamide (TN)

Cyclophosphamide (anhydrous form)

Cyclophosphamide (anhydrous)

Cyclophosphamide Monohydrate

Cyclophosphamide Sterile

Cyclophosphamide anhydrous

Cyclophosphamide, (+-)-Isomer

Cyclophosphamides

Cyclophosphamidum

Cyclophosphamidum [INN-Latin]

Cyclophosphan

Cyclophosphane

Cyclophosphanum

Cyclophosphoramide

Cyclostin

Cyklofosfamid

Cyklofosfamid [Czech]

Cytophosphan

Cytophosphane

Cytoxan

Cytoxan (TN)

Cytoxan Lyoph

D,L-Cyclophosphamide

D07760

DB00531

DivK1c_000246

EINECS 200-015-4

EU-0100238

Endoxan

Endoxan R

Endoxan-Asta

Endoxana

Endoxanal

Endoxane

Enduxan

Genoxal

HMS2090A12

HSDB 3047

Hexadrin

IDI1_000246

KBio1_000246

KBio2_001338

KBio2_003906

KBio2_006474

KBio3_001319

KBioGR_000888

KBioSS_001338

LS-1302

LS-99787

Ledoxina

Lopac-C-0768

Lopac0_000238

Lyophilized Cytoxan

Mitoxan

MolPort-001-783-420

N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide

N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

NCGC00015209-01

NCGC00015209-03

NCGC00015209-06

NCGC00091741-02

NCGC00091741-03

NCI-C04900

NCI60_002097

NINDS_000246

NSC 26271

NSC-26271

NSC26271

NSC273033

NSC273034

Neosar

Occupation, cyclophosphamide exposure

Procytox

RCRA waste no. U058

Rcra Waste Number U058

Rcra waste number U058

Revimmune

S1217_Selleck

SK 20501

SPBio_001071

STK177249

STOCK2S-91217

Semdoxan

Sendoxan

Senduxan

Spectrum2_001146

Spectrum3_000370

Spectrum4_000304

Spectrum5_000795

Spectrum_000858

UNII-6UXW23996M

WLN: T6MPOTJ BO BN2G2G

Zyklophosphamid

Zyklophosphamid [German]

bis(2-Chloroethyl)phosphami de cyclic propanolamide

bis(2-Chloroethyl)phosphamide cyclic propanolamide ester

cyclophosphamide

Dactinomycin

approved

Phase 3, Phase 2

50-76-0

2019, 457193

Synonyms:

(- )-actinomycin d

(-)-actinomycin d

-pentone

01815_FLUKA

1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine

2-amino-N,N'-bis(hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo(2,1-I)(1,4,7,10,13)oxatetra-azacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide

4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide

50-76-0

A1410_SIGMA

A4262_SIGMA

A9415_SIGMA

AC1L1CQX

AC1L9W52

ACT

ACT D

ACTINOMYCIN D

ACTINOMYCIN D AMP

ACTINOMYCIN-D

ACTO-D

ACon0_000471

ACon1_001004

AD (VAN)

AI3-26374

ActD

Actactinomycin A IV

Actactinomycin a Iv

Actinomycin 11 Cosmegen

Actinomycin 11 cosmegen

Actinomycin 7

Actinomycin A IV

Actinomycin Aiv

Actinomycin C (sub1)

Actinomycin C(sub1)

Actinomycin C1

Actinomycin D

Actinomycin D (JP15)

Actinomycin D deriv. of 3H-phenoxaocardazine

Actinomycin D, sodium deoxyribonucleic acid complex

Actinomycin I

Actinomycin I (sub1)

Actinomycin I(sub 1)

Actinomycin I(sub1)

Actinomycin I1

Actinomycin IV

Actinomycin Iv

Actinomycin X 1

Actinomycin X1

Actinomycin iv

Actinomycin-(threo-val-pro-sar-meval)

Actinomycin-?IV

Actinomycin-[threo-val-pro-sar-meval]

Actinomycindioic D Acid, Dilactone

Actinomycindioic D acid, dilactone

Acto-D

Antibiotic From Streptomyces Parvullus

Antibiotic from Streptomyces parvullus

BCBcMAP01_000155

BRD-A42383464-001-02-2

Bio1_000342

Bio1_000831

Bio1_001320

C06770

C62H86N12O16

CBiol_002056

CCRIS 9

CHEBI:123721

CHEBI:27666

CHEMBL1554

CHEMBL427947

CID2019

CID457193

COSMEGEN (TN)

CPD000469227

Chounghwamycin B

Cosmegen

D Actinomycin

D00214

DACTINOMYCIN

DB00970

DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA

Dactinomicina

Dactinomicina [INN-Spanish]

Dactinomycin

Dactinomycin (USP)

Dactinomycin D

Dactinomycin [USAN:BAN]

Dactinomycine

Dactinomycine [INN-French]

Dactinomycinum

Dactinomycinum [INN-Latin]

Dilactone Actinomycin D Acid

Dilactone Actinomycindioic D Acid

Dilactone actin omycindioic D acid

Dilactone actinomycin D acid

Dilactone actinomycindioic D acid

EINECS 200-063-6

FT-0080366

GNF-PF-1977

HBF 386

HBF 386 Meractinomycin

HBF 386 meractinomycin

HMS2052O17

HSDB 3220

LMPK14000005

LS-142

Lyovac Cosmegen

Lyovac cosmegen

MEGxm0_000350

MLS001424196

Meractinomycin

MolPort-001-739-741

MolPort-003-925-177

NCGC00025059-02

NCGC00090796-01

NCGC00161622-01

NCGC00161622-02

NCGC00169767-01

NCI-C04682

NCI60_030539

NP-005932

NSC 3053

NSC-3053

NSC191297

NSC3053

Neuro_000003

Oncostatin K

Oxamide

PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA

SAM001246846

SMP1_000005

SMR000469227

UNII-1CC1JFE158

UPCMLD-DP055

UPCMLD-DP055:001

UPCMLD-DP055:002

WLN: 16- AN FVN IVN LVO PVM SVTJ G1 J1 KY1&1 N1 RY1&1

X 97

actd

actinomycin D

actinomycin cl

actinomycin x i

actinomyein-theo-val-pro-sar-meval

dactinomyein d

o)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine

Doxorubicin

approved, investigational

Phase 3, Phase 2, Phase 1

1714

23214-92-8

31703

Synonyms:

(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside

(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione

111266-55-8

14-Hydroxydaunomycin

14-Hydroxydaunorubicine

14-hydroxydaunomycin

14-hydroxydaunorubicine

23214-92-8

23257-17-2

24385-08-8

25311-50-6

25316-40-9

25316-40-9 (hydrochloride)

29042-30-6

AC1L1M5T

AC1Q29OJ

ADM

ADR

Adriablastin

Adriacin (hydrochloride salt)

Adriamycin

Adriamycin PFS

Adriamycin PFS (hydrochloride salt)

Adriamycin RDF

Adriamycin RDF (hydrochloride salt)

Adriamycin Semiquinone

Adriamycin semiquinone

Adriblas tina

Adriblastin

Adriblastina

Adriblastina (TN)

Adriblastina (hydrochloride salt)

Aerosolized Doxorubicin

BPBio1_000502

BRD-K92093830-003-04-3

BSPBio_000456

BSPBio_001031

C01661

C27H29NO11

CCRIS 739

CHEBI:28748

CHEMBL179

CID31703

Caelyx

Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74

Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120

D03899

DB00997

DM2

DOX-SL

Doxil

Doxo

Doxorubicin

Doxorubicin (USAN/INN)

Doxorubicin HCl

Doxorubicin Hydrochloride

Doxorubicin [USAN:INN:BAN]

Doxorubicin citrate

Doxorubicin hydrochloride (hydrochloride salt)

Doxorubicin-P4/D10

Doxorubicin-P4/D10 conjugate

Doxorubicin-hLL1

Doxorubicin-hLL1 conjugate

Doxorubicina

Doxorubicina [INN-Spanish]

Doxorubicine

Doxorubicine [INN-French]

Doxorubicinum

Doxorubicinum [INN-Latin]

EINECS 245-495-6

FI 106

Farmablastina (hydrochloride salt)

HMS2089H06

HSDB 3070

Hydroxydaunomycin hydrochlor ide (hydrochloride salt)

Hydroxydaunomycin hydrochloride (hydrochloride salt)

Hydroxydaunorubicin

Hydroxydaunorubicin hydrochloride (hydrochloride salt)

JT9100000

LMPK13050001

LS-1029

LS-165655

MLS000759533

Myocet

NCI-C01514

NChemBio.2007.10-comp13

NDC 38242-874

NIOSH/JT9100000

NSC 123127

Prestwick0_000438

Prestwick1_000438

Prestwick2_000438

Prestwick3_000438

Probes1_000151

Probes2_000129

RDF Rubex

Resmycin

Rubex

Rubex (hydrochloride salt)

SMP1_000106

SPBio_002395

TLC D-99

ThermoDox

Triferric doxorubicin

UNII-80168379AG

adiblastine (hydrochloride salt)

adr iablatina (hydrochloride salt)

adriablastine (hydrochloride salt)

adriablatina (hydrochloride salt)

adriblatina (hydrochloride salt)

doxorubicin

nchembio809-comp5

Vincristine

approved, investigational

Phase 3, Phase 2, Phase 1

904

2068-78-2, 57-22-7

5978

Synonyms:

22-Oxovincaleukoblastin

22-Oxovincaleukoblastine

28379-27-3

57-22-7

AC1L1LJC

C07204

C46H56N4O10

CCRIS 5763

CHEBI:28445

CID5978

D08679

DB00541

EINECS 200-318-1

HMS2090E19

HSDB 3199

Indole alkaloid

LCR

LS-228

Leurocristine

Lilly 37231 (1:1 sulfate salt)

Liposomal Vincristine

Marqibo

NCGC00163700-01

NCI-C04864

NCI60_026703

NSC-67574

Onco TCS

Oncovin

Oncovin (1:1 sulfate salt)

Oncovine

Tecnocris

Tecnocris (TN)

UNII-5J49Q6B70F

VCR

VIN

Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine

Vincasar

Vincasar (1:1 sulfate salt)

Vincasar PFS

Vincrex

Vincrex (1:1 sulfate salt)

Vincristin

Vincristina

Vincristina [DCIT]

Vincristine (INN)

Vincristine Sulfate

Vincristine Sulfate PFS

Vincristine [INN:BAN]

Vincristinum

Vincristinum [INN-Latin]

Vincrstine

Vincrystine

Vinkristin

Z-D-Val-Lys(Z)-OH

vincristine

Lenograstim

approved

Phase 3, Phase 2, Phase 1

1202

135968-09-1

Synonyms:

G-CSF (CHO cell derived)

Glycosylated recombinant G-CSF

Glycosylated recombinant granulocyte colony stimulating factor

Granulocyte colony stimulating factor 3 (CHO cell derived)

Granulocyte colony-stimulating factor lenograstim

Lenograstim (genetical recombination)

Lenograstim rDNA

Etoposide

approved

Phase 3, Phase 1, Phase 2

1232

33419-42-0

36462

Synonyms:

(-)-Etoposide

121471-01-0

136598-18-0

201594-04-9

33419-42-0

35317-32-9

4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside

4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)

4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)

4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside

4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin

4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside

4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside

51854-34-3

76576-58-4

9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one

AB00438905

AC1L1FN8

AC1L1VT3

AC1L6246

AC1NR4OG

AC1O4WGG

AC1O7M1N

AC1Q47JJ

Ambap33419-42-0

BPBio1_000673

BRD-K37798499-001-02-5

BSPBio_000611

Bio1_000489

Bio1_000978

Bio1_001467

C01576

CCRIS 2392

CHEBI:4911

CHEBI:588795

CHEMBL44657

CID11758093

CID284997

CID3310

CID36462

CID5284558

CID6419930

CID6610299

CPD000112002

D00125

DB00773

DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,

Demethyl Epipodophyllotoxin Ethylidine Glucoside

Demethyl-epiodophyllotoxin ethylidene glucoside

Demethylepipodophyllotoxin-beta-D-ethylideneglucoside

E0675

E1383_SIGMA

EINECS 251-509-1

EPE

EPEG

ETOP

Epipodophyllotoxin

Epipodophyllotoxin VP-16213

Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside

Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside

Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)

Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)

Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)

Eposide

Eposin

Eposin, Vepesid, VP-16, Toposar, Etoposide

Etopol

Etopophos

Etopophos (phosphate salt)

Etoposid

Etoposide

Etoposide (JP15/USP/INN)

Etoposide (VP16)

Etoposide [USAN:INN:BAN:JAN]

Etoposido

Etoposido [INN-Spanish]

Etoposidum

Etoposidum [INN-Latin]

Etosid

HMS1569O13

HMS2052N05

HMS2089F14

HSDB 6517

I06-0248

KBioSS_002410

LS-1214

Lastet

MLS000049957

MLS001074951

MLS001424283

MLS002153463

MLS002207239

MLS002222184

MolPort-003-983-431

MolPort-004-905-001

MolPort-004-955-161

NCGC00025056-02

NChemBio.2007.10-comp19

NK 171

NSC 141540

NSC-141540

NSC141540

Prestwick0_000396

Prestwick1_000396

Prestwick2_000396

Prestwick3_000396

Prestwick_211

S1225_Selleck

SAM001246880

SMR000112002

SPBio_002532

ST056353

Toposar

UNII-6PLQ3CP4P3

VP 16

VP 16 (pharmaceutical)

VP 16-213

VP 16213

VP-16

VP-16-213

VePESID (TN)

VePesid

Vepesid

Vepesid J

Vepeside

ZINC03830818

ZINC03938684

Zuyeyidal

etoposide

nchembio.573-comp8

nchembio873-comp2

trans-Etoposide

Ifosfamide

approved

Phase 3, Phase 2, Phase 1

391

3778-73-2

3690

Synonyms:

(+-)-Ifosfamid

(+-)-Ifosphamide

(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

(D,L)-Ifosfamide

(R,S)-Ifosphamide

(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide

1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide

2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd

2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd

2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide

2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide

2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide

2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)

2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide

3,} 2-oxazaphosphorine oxide

3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide

3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide

3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide

3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide

3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide

3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide

36341-88-5

3778-73-2

84711-20-6

A 4942

AB00513932

AC-2113

AC1L1GHW

ASTA Z 4942

Ambap3778-73-2

Asta Z 4942

BPBio1_000865

BRN 0611835

BSPBio_000785

C07047

CAS-3778-73-2

CCRIS 352

CHEBI:5864

CHEMBL1024

CID3690

Cyfos

D00343

D007069

DB01181

EINECS 223-237-3

HMS1570H07

HMS2090M12

HMS2093N07

HSDB 7023

Holoxan

Holoxan 1000

I-Phosphamide

I06-0494

IFEX (TN)

Ifex

Ifosfamid

Ifosfamida

Ifosfamida [INN-Spanish]

Ifosfamide (JAN/USP/INN)

Ifosfamide Sterile

Ifosfamide [USAN:INN:BAN:JAN]

Ifosfamidum

Ifosfamidum [INN-Latin]

Ifosphamide

Ifsofamide

Iphosphamid

Iphosphamid(e)

Iphosphamide

Iso Endoxan

Iso-Endoxan

Isoendoxan

Isofosfamide

Isophosphamide

Isosfamide

LS-102

LS-99799

MJF 9325

MJF-9325

MLS002154021

Mitoxana

Mitoxana, Ifex, Ifosfamide

MolPort-003-666-704

N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide

N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide

N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid

N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]

N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide

N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide

N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide

N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide

N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine

NCGC00016639-01

NCGC00179435-01

NCI-C01638

NCI60_000233

NPFAPI-04

NSC 109,724

NSC 109724

NSC-109,724

NSC-109724

NSC109,724

NSC109724

Naxamide

Prestwick0_000833

Prestwick1_000833

Prestwick2_000833

Prestwick3_000833

S1302_Selleck

SMR001233348

SPBio_002706

STL058690

UNII-UM20QQM95Y

WLN: T6NPOTJ AM2G BO B2G

Z 4942

Z-4942

Z4942

ifosfamide

isosfamide

{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,

Melphalan

approved

Phase 3, Phase 2, Phase 1

712

148-82-3

4053, 460612

Synonyms:

(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid

(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid

148-82-3

3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine

3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine

3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine

3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine

3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine

3025 C.B.

3025 c.b

3223-07-2

4-(Bis(2-chloroethyl)amino)-L-phenylalanine

4-14-00-01689 (Beilstein Handbook Reference)

4-[Bis(2-chloroethyl)amino]-L-phenylalanine

4-[Bis-(2-chloroethyl)amino]-L-phenylalanine

AC1LA2OE

ALKERAN (TN)

AY3360000

Alanine Nitrogen Mustard

Alkeran

AmbotzHAA1563

At-290

BIDD:GT0044

BRD-K87827419-001-02-8

BRN 2816456

BSPBio_002407

C13H18Cl2N2O2

CB 3025

CB-3025

CCRIS 374

CHEBI:165415

CHEBI:28876

CHEMBL852

CID460612

D00369

DivK1c_000653

EINECS 205-726-3

HMS2090B09

HMS2091B16

HMS502A15

HSDB 3234

IDI1_000653

KBio1_000653

KBio2_000877

KBio2_003445

KBio2_006013

KBio3_001627

KBioGR_001284

KBioSS_000877

L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine

L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine

L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine

L-PAM

L-Phenylalanine mustard

L-Sarcolysin

L-Sarcolysine

L-Sarkolysin

LS-15868

LS-865

Levofalan

Levofolan

Levopholan

M2011_SIGMA

MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))

MLS001333666

MLS002153368

Melfalan

Melfalano

Melfalano [INN-Spanish]

Melphalan (JP15/USP/INN)

Melphalan [USAN:INN:BAN:JAN]

Melphalanum

Melphalanum [INN-Latin]

Mephalan

MolPort-003-665-535

NCGC00090757-01

NCGC00090757-02

NCGC00090757-03

NCI-C04853

NINDS_000653

NIOSH/AY3360000

NSC 241286

NSC 8806

NSC-8806

NSC241286

NSC8806

P-Di-(2-chloroethyl)amino-L-phenylalanine

P-L-Sarcolysin

P-N-Bis(2-chloroethyl)amino-L-phenylalanine

Phenylalanine mustard

Phenylalanine nitrogen mustard

Prestwick_1006

RCRA waste no. U150

Rcra waste number U150

SK-15673

SMP2_000174

SMR000058720

SPBio_000287

SPECTRUM1500382

Sarcolysine

Sarkolysin

Spectrum2_000074

Spectrum3_000684

Spectrum4_000882

Spectrum5_001601

Spectrum_000397

TL8001065

TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)

TRANSGENIC MODEL EVALUATION (MELPHALAN)

UNII-Q41OR9510P

melphalan

p-Bis(beta-chloroethyl)aminophenylalanine

p-Di-(2-chloroethyl)amino-L-phenylalanine

p-L-Sarcolysin

p-L-sarcolysine

p-N,N-bis(2-chloroethyl)amino-L-phenylalanine

p-N-Bis(2-chloroethyl)amino-L-phenylalanine

p-N-Di(chloroethyl)aminophenylalanine

p-N-di(chloroethyl)aminophenylala nine

phenylalanine nitrogen mu stard

Mechlorethamine

approved

Phase 3, Phase 2, Phase 1

377

51-75-2

4033

Synonyms:

.Beta.,.beta.'-Dichlorodiethyl-N-methylamine

1, 5-Dichloro-3-methyl-3-azapentane hydrochloride

126-85-2 (N-oxide)

2,2'-Dichloro-N-me

2,2'-Dichloro-N-methyldiethylamine

2,2'-Dichlorodiethyl-methylamine

2,2'-dichloro-N-methyldiethylamine

2-Chloro-N-(2-chloroethyl)-N-methylethanamine

302-70-5 (N-oxide, hydrochloride)

51-75-2

55-86-7 (HYDROCHLORIDE)

AC1L1H9H

Antimit

BRN 0605323

BSPBio_001947

Bis(2-chloroethyl)methylamine

Bis(beta-chloroethyl) methylamine

Bis(beta-chloroethyl)methylamine

C07115

C5H11Cl2N

CCRIS 447

CHEBI:28925

CHEMBL427

CID4033

Carolysine

Caryolysin

Caryolysine

Chloramine (the nitrogen mustard)

Chlorethazine

Chlormethine

Chlormethine (INN)

Chlormethine [INN:BAN]

Chlormethinum [INN-Latin]

Cloramin

Clormetina

Clormetina [INN-Spanish]

D07671

DB00888

Di(2-chloroethyl)methylamine

Dichlor amine

Dichloren

DivK1c_000759

EINECS 200-120-5

ENT-25294

Embechine

Embichin

HMS1920J15

HMS2091B04

HMS502F21

HN-2

HN2

HSDB 5083

I14-8708

IBS-L0033631

IDI1_000759

KBio1_000759

KBio2_001369

KBio2_003937

KBio2_006505

KBio3_001447

KBioGR_001448

KBioSS_001369

LS-7559

MBA

Me chloroethamine

Mebichloramine

Mechlorethamine

Mechlorethanamine

Mechloroethamine

Mecloretamina

Mecloretamina [Italian]

Methylbis(2-chloroethyl)amine

Methylbis(beta-chloroethyl)amine

Methyldi(2-chloroethyl)amine

Mitoxine (*Hydrochloride*)

MolPort-001-785-592

Mustargen

Mustine

Mustine note

Mutagen

N,N-Bis(2-chloroethyl)-N-methylamine

N,N-Bis(2-chloroethyl)methylamine

N,N-Di(chloroethyl)methylamine

N-Lost

N-Methyl lost

N-Methyl-2,2'-dichlorodiethylamine

N-Methyl-bis(2-chloroethyl)amine

N-Methyl-bis(beta-chloroethyl)amine

N-Methyl-bis-chloraethylamin

N-Methyl-bis-chloraethylamin [German]

N-Methyl-lost

N-Methyl-lost [German]

N-methyl-bis(2-chloroethyl)amine

NCGC00091835-02

NCGC00091835-03

NCGC00091835-04

NCGC00091835-05

NCI60_041682

NINDS_000759

NSC762

Nitol (*Hydrochloride*)

Nitrogen mustard

Nitrogen mustard (HN-2)

Nitrogranulogen

SPBio_000496

SPECTRUM1500375

Spectrum2_000448

Spectrum3_000484

Spectrum4_000924

Spectrum5_001702

Spectrum_000889

Stickstofflost (*Hydrochloride*)

Stickstofflost (ebewe)

T 1024

T-1024

TL 146

UNII-50D9XSG0VR

beta,Beta'-dichlorodiethyl-N-methylamine

beta,beta'-Dichlorodiethyl-N-methylamine

mechlorethamine

thyldiethylamine

β,β'-dichlorodiethyl-N-methylamine

Carboplatin

approved

Phase 3, Phase 1, Phase 2

1980

41575-94-4

10339178, 498142, 38904

Synonyms:

(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum

/h1-3H2,(H,7,8)(H,9,10)

1,1-Cyclobutanedicarboxylate diammine platinum (II)

1,1-Cyclobutanedicarboxylate diammine platinum(II)

2*-1

2*1H2

41575-94-4

70903-55-8

AC-1457

AC1L8I6U

Ambap41575-94-4

BSPBio_003145

C 2538

C2043

C2538_SIGMA

C6H10N2O4Pt

CBDCA

CCRIS 3404

CHEBI:31355

CHEMBL1351

CHEMBL288376

CID10339178

CID2567

CID38904

CID426756

CID498142

CID5352133

CID6398587

CID6603770

Carbopaltin

Carboplatin

Carboplatin (JAN/USP/INN)

Carboplatin (USAN)

Carboplatin [USAN:INN:BAN:JAN]

Carboplatine

Carboplatine [French]

Carboplatino

Carboplatino [Spanish]

Carboplatinum

Carboplatinum [Latin]

Cbdca

Cyclobutane-1,1-dicarboxylate

D01363

DB00958

Diammine(1,1-cyclobutanedicarboxylato)platinum (II)

Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum

Diammine-1,1-cyclobutane dicarboxylate platinum II

DivK1c_000892

EINECS 255-446-0

EU-0100230

Ercar

HMS1921J16

HMS2090M05

HMS2092B22

HMS502M14

HSDB 6957

I14-2390

IDI1_000892

IUPAC: Azane

InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6

JM 8

JM-8

KBio1_000892

KBio2_002009

KBio2_004577

KBio2_007145

KBio3_002645

KBioGR_000713

KBioSS_002009

LS-117689

Lopac-C-2538

Lopac0_000230

MolPort-003-665-501

MolPort-003-845-609

NCGC00015223-01

NCGC00093695-01

NCGC00094961-01

NCGC00094961-02

NCGC00094961-03

NCGC00162099-01

NCGC00162099-02

NCGC00167800-01

NCGC00178242-01

NINDS_000892

NSC 201345

NSC 241240

NSC-241240

NSC201345

NSC241240

Paraplatin

Paraplatin (TN)

Paraplatin, Carboplatin

Paraplatin-AQ

Platinum(+2) Cation

Platinum(II), (1, 1-cyclobutanedicar

Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)

Platinum, {diammine[1,1-cyclobut

S1215_Selleck

SPBio_000716

SPECTRUM1502106

Spectrum2_000898

Spectrum3_001503

Spectrum4_000337

Spectrum5_001094

Spectrum_001529

UNII-BG3F62OND5

azanide

carboplatin

cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum

cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)

cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)

cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)

cis-Diammine(1,1-cyclobutanedicarboxylato) platinum

cis-Diammine(1,1-cyclobutanedicarboxylato)platinum

cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diammine(cyclobutanedicarboxylato)platinum II

cyclobutane-1,1-dicarboxylic acid

diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum

nchembio.573-comp10

nchembio773-comp2

nchembio873-comp3

platinum(2+)

Busulfan

approved, investigational

Phase 3, Phase 2, Phase 1

540

55-98-1

2478

Synonyms:

1, 4-Dimethanesulfonoxybutane

1, 4-Dimethylsulfonoxybutane

1, {4-Bis[methanesulfonoxy]butane}

1,4-BUTANEDIOL DIMETHANESULFONATE

1,4-Bis(methanesulfonoxy)butane

1,4-Bis(methanesulfonyloxy)butane

1,4-Bis[methanesulfonoxy]butane

1,4-Butanedi yl dimethanesulfonate

1,4-Butanediol dimethanesulfonate

1,4-Butanediol dimethanesulphonate

1,4-Butanediol dimethylsulfonate

1,4-Butanediol, dimethanesulfonate

1,4-Butanediol, dimethanesulphonate

1,4-Butanediyl dimethanesulfonate

1,4-Di(methylsulfonoxy)butane

1,4-Dimesyloxybutane

1,4-Dimethane sulfonyl oxybutane

1,4-Dimethanesulfonoxybutane

1,4-Dimethanesulfonoxylbutane

1,4-Dimethanesulfonyloxybutane

1,4-Dimethanesulphonyloxybutane

1,4-Dimethylsulfonoxybutane

1,4-Dimethylsulfonyloxybutane

2041 C. B

2041 C. B.

2041 C.B

2041 C.B.

4-((Methylsulfonyl)oxy)butyl methanesulfonate

4-methylsulfonyloxybutyl methanesulfonate

55-98-1

AC-198

AC1L1DRQ

AC1Q4GRQ

AI3-25012

AKOS003614975

AN 33501

Ambap55-98-1

B1022

B2635_FLUKA

B2635_SIGMA

BRN 1791786

BSPBio_001920

BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)

Bisulfex

Busilvex

Busulfan

Busulfan (JP15/USP/INN)

Busulfan GlaxoSmithKline Brand

Busulfan Orphan Brand

Busulfan Wellcome

Busulfan Wellcome Brand

Busulfan [INN:JAN]

Busulfano

Busulfano [INN-Spanish]

Busulfanum

Busulfanum [INN-Latin]

Busulfex

Busulphan

Busulphane

Butanedioldimethanesulfonate

Buzulfan

C.B. 2041

C6H14O6S2

CB 2041

CCRIS 418

CHEBI:28901

CHEMBL820

CID2478

CPD000058613

Citosulfan

D002066

D00248

DB01008

DivK1c_000847

EINECS 200-250-2

FT-0083567

G.T. 41

GT 2041

GT 41

Glaxo Wellcome Brand of Busulfan

GlaxoSmithKline Brand of Busulfan

Glyzophrol

HMS1920I07

HMS2091O09

HMS502K09

HSDB 7605

I09-1371

IDI1_000847

InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3

KBio1_000847

KBio2_000512

KBio2_003080

KBio2_005648

KBio3_001420

KBioGR_000698

KBioSS_000512

LS-1358

Leucosulfan

MLS001076666

MYLERAN (TN)

Mablin

Methanesulfonic

Methanesulfonic acid, tetram ethylene ester

Methanesulfonic acid, tetramethylene ester

Mielevcin

Mielosan

Mielucin

Milecitan

Mileran

Misulban

Mitosan

Mitostan

MolPort-001-783-406

Myeleukon

Myeloleukon

Myelosan

Myelosanum

Mylecytan

Myleran

Myleran Tablets

Myleran tablets

Myleran, Busulfex, Busulfan

Mylerlan

NCGC00090905-01

NCGC00090905-02

NCGC00090905-03

NCGC00090905-04

NCGC00090905-05

NCGC00090905-06

NCGC00090905-07

NCI-C01592

NCI60_041640

NCIMech_000192

NINDS_000847

NSC 750

NSC-750

NSC-750sulphabutin

NSC750

Orphan Brand of Busulfan

Prestwick_989

S1692_Selleck

SAM002554887

SMR000058613

SPBio_000253

SPECTRUM1500152

ST50825921

Spectrum2_000067

Spectrum3_000320

Spectrum4_000259

Spectrum5_000928

Spectrum_000092

Sulfabutin

Sulfabutin (VAN)

Sulphabutin

Tetramethylene Dimethane Sulfonate

Tetramethylene bis(methanesulfonate)

Tetramethylene bis[methanesulfonate]

Tetramethylene dimethane sulfonate

Tetramethylene {bis[methanesulfonate]}

Tetramethylenester Kyseliny Methansulfonove

Tetramethylenester kyseliny methansulfonove

Tetramethylenester kyseliny methansulfonove [Czech]

UNII-G1LN9045DK

WLN: WS1&O4OSW1

Wellcome Brand of Busulfan

Wellcome, Busulfan

X 149

acid, tetramethylene ester

alkylating agent: crosslinks guanine residues

busulfan

butane-1,4-diyl dimethanesulfonate

n-Butane-1,3-di(methylsulfonate)

Histamine

approved

Phase 3

1034

75614-87-8, 51-45-6

774

Synonyms:

.beta.-Imidazolyl-4-ethylamine

1H-Imidazole-4-ethanamine

1H-Imidazole-5-ethanamine

1avn

1qft

2-(1H-Imidazol-4-yl)ethanamine

2-(1H-Imidazol-4-yl)ethylamine

2-(1H-Imidazol-5-yl)ethanamine

2-(1H-Imidazol-5-yl)ethylamine

2-(1H-imidazol-4-yl)ethan-1-amine

2-(1H-imidazol-5-yl)ethanamine

2-(3H-Imidazol-4-yl)-ethylamine

2-(4-Imidazolyl)ethanamine

2-(4-Imidazolyl)ethylamine

2-Imidazol-4-yl-Ethylamine

2-Imidazol-4-ylethylamine

2-[4-Imidazolyl]ethylamine

4-(2-Aminoethyl)-1H-imidazole

4-(2-Aminoethyl)imidazole

4-Imidazoleethylamine

5-Imidazoleethylamine

51-45-6

53290_FLUKA

64422-25-9

924364-91-0

AC-13185

AC1L19ZT

AC1Q54BV

AC1Q54BW

AKOS000274386

ALBB-005968

BCBcMAP01_000250

BSPBio_001117

BSPBio_002124

Bio1_000487

Bio1_000976

Bio1_001465

Bio2_000389

Bio2_000869

C00388

CCRIS 6535

CHEBI:18295

CHEMBL90

CID774

D08040

DivK1c_000308

EINECS 200-100-6

Eramin

Ergamine

Ergotidine

F411C768-A159-4FC0-A195-291A08BB03AA

Free histamine

H7125_SIGMA

HMS1362G19

HMS1792G19

HMS1990G19

HSDB 3338

HSM

Histamine

Histamine (DCF)

Histamine Base

Histamine [USAN]

Histamine, Free Base

Histaminum

Histaminum (TN)

IDI1_000308

IDI1_002144

Imidazole-4-ethylamine

Istamina

Istamina [Italian]

KBio1_000308

KBio2_000457

KBio2_001325

KBio2_003025

KBio2_003893

KBio2_005593

KBio2_006461

KBio3_000853

KBio3_000854

KBio3_001344

KBioGR_000457

KBioGR_001580

KBioSS_000457

KBioSS_001325

L-Histamin base

L-Histamine

L-histamine

L000292

LS-75835

Lopac-H-7250

Lopac0_000595

MLS000069447

MolPort-001-785-597

MolPort-002-042-264

NCGC00015513-01

NCGC00015513-08

NCGC00093371-02

NCGC00093371-03

NCGC00093371-04

NCGC00093371-05

NINDS_000308

NSC 33792

NSC33792

SDCCGMLS-0066601.P001

SMP1_000151

SMR000059091

SPBio_000729

ST073926

STK346752

STOCK5S-55669

Spectrum2_000665

Spectrum3_000452

Spectrum4_000960

Spectrum5_000796

Spectrum_000845

Theramine

UNII-820484N8I3

WLN: T5M CNJ D2Z

ZERO/004089

[3H]histamine

b-Imidazolyl-4-ethylamine

beta-Aminoethylglyoxaline

beta-Aminoethylimidazole

beta-Aminothethylglyoxaline

beta-Imidazolyl-4-ethylamine

beta-aminothethylglyoxaline

bmse000744

histamine

nchembio.87-comp54

nchembio714-comp1

Topotecan

approved, investigational

Phase 3, Phase 2, Phase 1

339

119413-54-6, 123948-87-8

60700

Synonyms:

(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione

(S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione

(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE

(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione

(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione

123948-87-8

9-Dimethylaminomethyl-10-hydroxycamptothecin

9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin

AC-11592

AC1L1TQZ

AC1Q6APZ

BSPBio_002348

C11158

C23H23N3O5

CCRIS 8163

CHEBI:107501

CHEBI:46035

CHEMBL84

CID60700

D08618

DB01030

HMS2090B20

HSCI1_000228

Hycamptamine

Hycamptin

Hycamtamine

Hycamtin

Hycamtin (TN)

LS-127395

MLS000759456

NCGC00178695-01

NCI60_004771

NCIStruc1_001659

NCIStruc2_001796

NChemBio.2007.10-comp24

NSC609699

SK&F-104864-A

SKF 104864

SKF-104864-A

SKF-S 104864

SMP2_000312

SMP2_000327

SMR000466344

TOPO

TOPOTECAN, HYCAMTIN

TPT

TTC

Topotecan (BAN)

Topotecan Hcl

Topotecan Hydrochloride

Topotecan Lactone

Topotecan Monohydrochloride, (S)-Isomer

Topotecan [INN:BAN]

Topotecan lactone

Topotecane

Topotecane [INN-French]

Topotecanum

Topotecanum [INN-Latin]

UNII-7M7YKX2N15

topotecan

Histamine Phosphate

approved

Phase 3

1033

51-74-1

65513

Synonyms:

1H-Imidazole-4-ethanamine, phosphate (1:2)

2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)

4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)

4-(2-Aminoethyl)imidazole di-acid phosphate

4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate

51-74-1

53623-99-7

74-56-6

AC1L23E4

CID65513

D04445

DB00667

EINECS 200-118-4

H0147

Histamine acid phosphate

Histamine biphosphate

Histamine dihydrogen phosphate

Histamine diphosphate

Histamine phosphate (1:2)

Histamine phosphate (TN)

Histamine phosphate (USP)

Histamine phosphate [USP]

Histamine positive

Histaminum

LS-78569

UNII-QWB37T4WZZ

Fentanyl

approved, illicit, investigational, vet_approved

Phase 3

773

437-38-7

3345

Synonyms:

1-Phenethyl-4-(N-phenylpropionamido)piperidine

1-Phenethyl-4-N-propionylanilinopiperidine

1-phenethyl-4-N-propionylanilinopiperidine

437-38-7

5-22-08-00049 (Beilstein Handbook Reference)

80832-90-2

990-73-8 (citrate)

AC1L1FQ2

Actiq

BIDD:GT0555

BRN 0494484

CHEBI:119915

CHEMBL596

CID3345

D00320

DB00813

Duragesic

Duragesic (TN)

Duragesic-100

Duragesic-12

Duragesic-25

Duragesic-50

Duragesic-75

Durogesic

EINECS 207-113-6

Fentanest

Fentanil

Fentanil [DCIT]

Fentanila

Fentanila [INN-Spanish]

Fentanilo

Fentanyl

Fentanyl (JAN/USAN/INN)

Fentanyl CII

Fentanyl [INN:BAN]

Fentanyl citrate

Fentanyl-100

Fentanyl-12

Fentanyl-25

Fentanyl-50

Fentanyl-75

Fentanylum

Fentanylum [INN-Latin]

HSDB 3329

IONSYS

JNS020QD

L001275

LS-124439

Matrifen

MolPort-003-847-369

N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide

N-(1-Phenethyl-4-piperidyl)propionanilide

N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide

N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide

N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide

N-(1-phenethyl-4-piperidyl)propionanilide

N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide

N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide

N-Phenethyl-4-(N-propionylanilino)piperidine

N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide

N-phenethyl-4-(N-propionylanilino)piperidine

N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide

N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide

NCGC00168252-01

Nasalfent

Oprea1_152073

Oprea1_207148

PDSP1_000860

PDSP2_000846

Pentanyl

Phentanyl

Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)

R 4263

Rapinyl

Sentonil

Sublimase

Sublimaze

UNII-UF599785JZ

fentanyl

Epirubicin

approved

Phase 3, Phase 2

383

56420-45-2

41867

Synonyms:

(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside

(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside

(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione

(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione

10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione

4'-Epi-DXR

4'-Epiadriamycin

4'-Epidoxorubicin

4'-epi-DX

4'-epi-Doxorubicin

4'-epidoxorubicin

4-Epidoxorubicin

56390-09-1

56390-09-1 (hydrochloride)

56420-45-2

57918-25-9

AC1L26NP

AC1Q6JIV

BRN 1445813

C11230

C27H29NO11

CCRIS 2261

CHEBI:47898

CHEMBL417

CID41867

D07901

DB00445

Ellence

Epi-DX

Epi-Dx

Epiadriamycin

Epidoxorubicin

Epirubicin

Epirubicin (INN)

Epirubicin [INN:BAN]

Epirubicina

Epirubicina [INN-Spanish]

Epirubicina [Spanish]

Epirubicine

Epirubicine [French]

Epirubicine [INN-French]

Epirubicinum

Epirubicinum [INN-Latin]

Epirubicinum [Latin]

Farmorubicin (TN)

HSDB 6962

IMI 28

LS-187190

LS-93992

MLS000759412

NChemBio.2007.10-comp15

NSC 256942

NSC-256942

NSC256942

Pharmorubicin Pfs

Pidorubicin

Pidorubicina

Pidorubicina [INN-Spanish]

Pidorubicine

Pidorubicine [INN-French]

Pidorubicinum

Pidorubicinum [INN-Latin]

Ridorubicin

SMR000466308

Triferric doxorubicin

UNII-3Z8479ZZ5X

WP 697

Idarubicin

approved

Phase 3

210

58957-92-9

42890

Synonyms:

(1S,3S)-3-Acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside

(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside

(1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-|A-l-lyxo-hexopyranoside

(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione

(7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione

4-DMD

4-Demethoxydaunomycin

4-Demethoxydaunorubicin

4-Desmethoxydaunorubicin

57852-57-0

57852-57-0 (HYDROCHLORIDE)

58957-92-9

AC1L28SA

AC1Q6JJ4

BRD-K69650333-001-01-1

C26H27NO9

CCRIS 5083

CHEBI:42068

CHEMBL1117

CID42890

D08062

DB01177

DM5

DMDR

EU-0100600

HMS2089D05

I 1656

I06-1097

I1656_SIGMA

IDARUBICIN

IMI 30

IMI-30

Idamycin

Idamycin PFS

Idarubicin (INN)

Idarubicin Aglycone

Idarubicin HCl PFS

Idarubicin Hcl

Idarubicin Hcl Pfs

Idarubicin Hydrochloride

Idarubicin [INN:BAN]

Idarubicina

Idarubicina [INN-Spanish]

Idarubicine

Idarubicine [INN-French]

Idarubicinum

Idarubicinum [INN-Latin]

KBioSS_002388

LS-94015

Lopac0_000600

MLS000759470

NCGC00093976-01

NCGC00093976-02

NCGC00093976-03

NCGC00093976-04

NSC-256439

NSC256439

SMR000466355

UNII-ZRP63D75JW

Zavedos

Zavedos (TN)

idarubicin hydrochloride

Zoledronic acid

approved

Phase 3, Phase 1

290

118072-93-8

68740

Synonyms:

(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid

(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid

(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid

(1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate

(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid

118072-93-8

2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid

2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid

AC-1092

AC1L2ACJ

AC1Q6RN3

AKOS005145739

Aclasta

Anhydrous Zoledronic Acid

BIDD:GT0292

BIDD:PXR0134

Bio-0112

Bisphosphonate 3

C088658

CGP 42'446

CGP 42446

CGP 42446A

CGP-42'446

CGP-42446

CHEBI:46557

CHEMBL924

CID68740

D08689

DB00399

FT-0082657

HMS2089O09

I06-0710

KS-1132

LS-181815

MolPort-002-885-874

MolPort-003-850-890

NCGC00159521-02

NCGC00159521-03

NSC721517

Novartis brand of zoledronic acid

Reclast

Reclast (TN)

S00092

S1314_Selleck

UNII-70HZ18PH24

ZOL

Zol

Zoledronate

Zoledronic Acid Anhydrous

Zoledronic Acid, Anhydrous

Zoledronic acid

Zoledronic acid (INN)

Zoledronic acid [USAN:INN]

Zometa

Zometa (Novartis)

Zometa (TN)

Zometa Concentrate

Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid

[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)

Cyproheptadine

approved

Phase 3

129-03-3

2913

Synonyms:

1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine

1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine

1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine

129-03-3

4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine

4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine

4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine

4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene

4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine

4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine

4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine

4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine

41354-29-4

5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene

5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene

5-20-08-00500 (Beilstein Handbook Reference)

AC1L1ER8

AKOS004119847

Axoprol

BIDD:GT0324

BPBio1_000096

BPBio1_000155

BRD-K28143534-001-01-4

BRD-K28143534-003-03-6

BRN 1685976

BSPBio_000086

Biomol-NT_000131

C06935

CAS-969-33-5

CCRIS 5232

CHEBI:4046

CHEMBL516

CID2913

CYPROHEPTADINE

Ciproheptadina

Ciproheptadina [INN-Spanish]

Ciprovit

Ciprovit (TN)

Cypoheptadine

Cyproheptadiene

Cyproheptadin

Cyproheptadine

Cyproheptadine (INN)

Cyproheptadine Hcl

Cyproheptadine [INN:BAN]

Cyproheptadinum

Cyproheptadinum [INN-Latin]

D07765

DB00434

Dibenzosuberonone/Cyproheptadine

Dihexazin

Dronactin

EINECS 204-928-9

Eiproheptadine

Glutodina

HMS2090P20

HSDB 3048

L001016

LS-114933

Lopac-C-6022

Lopac0_000246

MK 141

MolPort-002-507-777

NCGC00015252-01

NCGC00015252-02

NCGC00015252-03

NCGC00015252-09

NCGC00024293-02

NCGC00024293-04

NCGC00024293-05

Oprea1_498140

PDSP1_001229

PDSP2_001213

Periactin

Periactine

Periactinol

Prestwick0_000103

Prestwick1_000103

Prestwick2_000103

Prestwick3_000103

SPBio_002025

STK802098

Tocris-0996

UNII-2YHB6175DO

Viternum

nchembio.559-comp10

Doxil

Approved June 1999

Phase 3, Phase 2, Phase 1

1714

31703

Synonyms:

Dox-SL

Doxil

Evacet

LipoDox

Pegylated Liposomal Doxorubicin Hydrochloride

liposomal doxorubicin

Antineoplastic Agents, Hormonal

Phase 2, Phase 3, Phase 1

5407

Gastrointestinal Agents

Phase 3, Phase 2, Phase 1

8109

Protective Agents

Phase 3, Phase 2, Phase 1

7190

Liver Extracts

Phase 3, Phase 2, Phase 1

3868

Peripheral Nervous System Agents

Phase 3, Phase 2, Phase 1

22776

Isophosphamide mustard

Phase 3, Phase 2, Phase 1

391

Anti-Bacterial Agents

Phase 3, Phase 2, Phase 1

10884

Cobalt

Phase 3, Phase 2

165

7440-48-4

104729

Synonyms:

Aquacat

Cobalt-59

Cobatope-57

Kobalt

Super cobalt

Antirheumatic Agents

Phase 3, Phase 1, Phase 2

10627

Antineoplastic Agents, Phytogenic

Phase 3, Phase 2, Phase 1

5420

Antimitotic Agents

Phase 3, Phase 2, Phase 1

5498

Antineoplastic Agents, Alkylating

Phase 3, Phase 1, Phase 2

4474

Etoposide phosphate

Phase 3, Phase 1, Phase 2

1232

Immunosuppressive Agents

Phase 3, Phase 1, Phase 2

12770

Adjuvants, Immunologic

Phase 3, Phase 2, Phase 1

2484

Topoisomerase Inhibitors

Phase 3, Phase 2, Phase 1

4945

Interventional clinical trials:

(show top 50) (show all 252)

id	Name	Status	NCT ID	Phase
1	Dolutegravir and Darunavir Evaluation in Adults Failing Therapy	Not yet recruiting	NCT03017872	Phase 4
2	Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma	Unknown status	NCT00002516	Phase 3
3	Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma	Unknown status	NCT00020566	Phase 3
4	Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor	Completed	NCT00006734	Phase 3
5	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3
6	Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant	Completed	NCT00305851	Phase 3
7	Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma	Completed	NCT00002898	Phase 3
8	Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma	Recruiting	NCT02063022	Phase 3
9	Study in Localized and Disseminated Ewing Sarcoma	Recruiting	NCT00987636	Phase 3
10	Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma	Recruiting	NCT02306161	Phase 3
11	Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer	Recruiting	NCT02856048	Phase 2, Phase 3
12	Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma	Recruiting	NCT00876031	Phase 3
13	Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma	Suspended	NCT01231906	Phase 3
14	Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer	Terminated	NCT01132547	Phase 3
15	Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients	Withdrawn	NCT01734863	Phase 3
16	Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma	Withdrawn	NCT00334867	Phase 3
17	Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas	Unknown status	NCT00998361	Phase 2
18	Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse	Unknown status	NCT00180947	Phase 2
19	Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors	Unknown status	NCT00003515	Phase 2
20	Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors	Unknown status	NCT00179816	Phase 1, Phase 2
21	Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases	Unknown status	NCT00084695	Phase 2
22	Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy	Completed	NCT01222767	Phase 2
23	Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor	Completed	NCT00062205	Phase 2
24	Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors	Completed	NCT00560235	Phase 1, Phase 2
25	Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors	Completed	NCT00070109	Phase 2
26	Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors	Completed	NCT00061893	Phase 2
27	Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma	Completed	NCT01583543	Phase 2
28	New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma	Completed	NCT00001335	Phase 2
29	Aerosol L9-NC and Temozolomide in Ewing's Sarcoma	Completed	NCT00492141	Phase 1, Phase 2
30	Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma	Completed	NCT00276692	Phase 2
31	Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma	Completed	NCT00516295	Phase 2
32	Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma	Completed	NCT00470275	Phase 2
33	Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors	Completed	NCT00357396	Phase 2
34	Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor	Completed	NCT00002643	Phase 2
35	Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma	Completed	NCT00073983	Phase 2
36	Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone	Completed	NCT00006234	Phase 1, Phase 2
37	Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma	Completed	NCT00003667	Phase 2
38	Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor	Completed	NCT00055952	Phase 2
39	Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer	Completed	NCT00002466	Phase 2
40	A Study of R1507 in Patients With Recurrent or Refractory Sarcoma.	Completed	NCT00642941	Phase 2
41	A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma	Completed	NCT00668148	Phase 2
42	QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors	Completed	NCT00563680	Phase 2
43	A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas	Completed	NCT00001566	Phase 2
44	A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas	Completed	NCT00001564	Phase 2
45	Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas	Completed	NCT00165139	Phase 2
46	A Study of Pemetrexed in Children With Recurrent Cancer	Completed	NCT00520936	Phase 2
47	Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	Completed	NCT01136499	Phase 2
48	Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma	Completed	NCT00006102	Phase 2
49	Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors	Completed	NCT00831844	Phase 2
50	Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas	Completed	NCT00043979	Phase 2

Search NIH Clinical Center for Ewing's Family of Tumors

Genetic Tests for Ewing's Family of Tumors

Anatomical Context for Ewing's Family of Tumors

Sources:
³⁶MalaCards
See all MalaCards sources

MalaCards organs/tissues related to Ewing's Family of Tumors:

³⁶

Bone, Nk cells, Lung, T cells, Brain, Kidney, Liver

Publications for Ewing's Family of Tumors

Sources:
⁵⁷PubMed
See all MalaCards sources

Articles related to Ewing's Family of Tumors:

(show all 13)

id	Title	Authors	Year
1	High-dose chemotherapy and stem cell rescue for high-risk Ewing's family of tumors. (21342043)	Rosenthal J.... Pawlowska A.B.	2011
2	Ewing's family of tumors of the sinonasal tract and maxillary bone. (21107767)	Hafezi S.... Weinreb I.	2011
3	Immunophenotypic profile of biomarkers related to anti-apoptotic and neural development pathways in the Ewing's family of tumors (EFT) and their therapeutic implications. (17695539)	Navarro S.... Llombart-Bosch A.	2007
4	Single center experience of treatment of Ewing's family of tumors in Japan. (16437346)	Yamada K.... Takahashi M.	2006
5	Prognostic and therapeutic targets in the Ewing's family of tumors (PROTHETS). (17163151)	Picci P.... Rizzi A.	2006
6	High-dose therapy and stem-cell rescue for Ewing's family of tumors in second remission. (15781877)	Marina N.... Meyers P.A.	2005
7	EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. (15930281)	Hu-Lieskovan S.... Triche T.J.	2005
8	Megatherapy and stem cell transplantation for Ewing's family of tumors: a critical review of current literature. (15125709)	Kalambakas S.A.... Feig S.A.	2004
9	Single center experience of a new intensive induction therapy for ewing's family of tumors: feasibility, toxicity, and stem cell mobilization properties. (12885818)	Strauss S.J.... Whelan J.S.	2003
10	Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. (12972518)	Kolb E.A.... Meyers P.A.	2003
11	Ewing's family of tumors involving structures related to the central nervous system: a review. (10742406)	Hadfield M.G.... Luo V.Y.	2000
12	Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital. (10458232)	Marina N.M.... Meyer W.H.	1999
13	Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. (9850016)	Fizazi K.... Nguyen B.B.	1998

Genes related to Ewing's Family of Tumors

Sources:
²¹GeneCards
See all MalaCards sources

Genes related to Ewing's Family of Tumors:

(show all 14)

- Elite gene

- Cancer Census gene in COSMIC

id	Symbol	Description	Score	Implication
1	EWSR1	EWS RNA Binding Protein 1	18.62	GeneCards inferred via : Publications (show sections)
2	FLI1	Fli-1 Proto-Oncogene, ETS Transcription Factor	18.42	GeneCards inferred via : Publications (show sections)
3	KITLG	KIT Ligand	18.07	GeneCards inferred via : Publications (show sections)
4	MTOR	Mechanistic Target Of Rapamycin	18.07	GeneCards inferred via : Publications (show sections)
5	FAS	Fas Cell Surface Death Receptor	18.07	GeneCards inferred via : Publications (show sections)
6	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	18.07	GeneCards inferred via : Publications (show sections)
7	CDK4	Cyclin Dependent Kinase 4	18.07	GeneCards inferred via : Publications (show sections)
8	KIT	KIT Proto-Oncogene Receptor Tyrosine Kinase	18.07	GeneCards inferred via : Publications (show sections)
9	EPOR	Erythropoietin Receptor	18.07	GeneCards inferred via : Publications (show sections)
10	EPO	Erythropoietin	18.07	GeneCards inferred via : Publications (show sections)
11	CDKN2B	Cyclin Dependent Kinase Inhibitor 2B	18.07	GeneCards inferred via : Publications (show sections)
12	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	18.07	GeneCards inferred via : Publications (show sections)
13	RB1	RB Transcriptional Corepressor 1	18.07	GeneCards inferred via : Publications (show sections)
14	CSF3	Colony Stimulating Factor 3	8.07	GeneCards inferred via : Publications (show sections)

Variations for Ewing's Family of Tumors

Expression for genes affiliated with Ewing's Family of Tumors

Sources:
¹⁸Gene Expression Omnibus DataSets
See all MalaCards sources

Search GEO for disease gene expression data for Ewing's Family of Tumors.

Pathways for genes affiliated with Ewing's Family of Tumors

Sources:
³Cell Signaling Technology, ³⁴KEGG, ⁴²NCBI BioSystems Database, ⁵⁵PathCards, ⁵⁸QIAGEN, ⁵⁹R&D Systems, ⁶⁰Reactome, ⁶⁵Thomson Reuters
See all MalaCards sources

Pathways related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

(show all 35)

id	Super pathways	Score	Top Affiliating Genes
1	Regulation of KIT signaling⁶⁰	9.8	KIT, KITLG
2	Tyrosine Kinases / Adaptors³	9.5	ERBB2, KIT, KITLG
3	Central carbon metabolism in cancer³⁴	9.5	ERBB2, KIT, MTOR
4	HIF-1 signaling pathway³⁴	9.4	EPO, ERBB2, MTOR
5	NF-kappaB Signaling³	9.3	FAS, FLI1, KIT, KITLG
6	Inhibition of Ribosome Biogenesis by p14(ARF)⁵⁸	9.0	CDKN2A, RB1
7	Integrated Breast Cancer Pathway⁴²	9.0	CDK4, MTOR, RB1
8	TSH signaling pathway⁴²	9.0	CDK4, MTOR, RB1
9	Oncogene Induced Senescence⁶⁰	9.0	CDK4, CDKN2A, CDKN2B
10	Integrated Pancreatic Cancer Pathway⁴²	9.0	CDK4, CDKN2B, ERBB2, FAS
11	Development Angiotensin activation of ERK⁶⁵ Show member pathways Development G-Proteins mediated regulation MARK-ERK signaling⁶⁵ Development EPO-induced MAPK pathway⁶⁵ Development EDNRB signaling⁶⁵ Cell adhesion Integrin inside-out signaling⁶⁵ Development ACM2 and ACM4 activation of ERK⁶⁵ Development Angiotensin signaling via PYK2⁶⁵ Signal transduction IP3 signaling⁶⁵	9.0	EPO, EPOR, KIT, KITLG
12	Kit Receptor Signaling Pathway⁴² Show member pathways Signaling events mediated by Stem cell factor receptor (c-Kit)⁴² IL-3 Signaling Pathway⁴²	9.0	EPO, EPOR, KIT, KITLG
13	p53 Pathway (RnD)⁵⁹ Show member pathways p53 Pathway⁵⁹	8.9	CDK4, CDKN2A, FAS, MTOR
14	Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers⁵⁹	8.9	CSF3, EPO, KIT, KITLG
15	Small cell lung cancer³⁴	8.8	CDK4, CDKN2B, RB1
16	Senescence and Autophagy⁴²	8.7	CDKN2A, MTOR, RB1
17	MAPK Signaling: Mitogen Stimulation Pathway⁵⁹ Show member pathways Akt Signaling Pathway⁵⁹	8.7	CDK4, ERBB2, MTOR, RB1
18	Hematopoietic cell lineage³⁴	8.4	CSF3, EPO, EPOR, KIT, KITLG
19	Glioblastoma Multiforme⁵⁸	8.4	CDK4, CDKN2A, MTOR, RB1
20	Bladder cancer³⁴	8.4	CDK4, CDKN2A, ERBB2, RB1
21	Chronic myeloid leukemia³⁴ Show member pathways Pancreatic cancer³⁴	8.4	CDK4, CDKN2A, ERBB2, RB1
22	Mitotic G1-G1/S phases⁶⁰ Show member pathways G1/S Transition⁶⁰	8.2	CDK4, CDKN2A, CDKN2B, RB1
23	HTLV-I infection³⁴	8.2	CDK4, CDKN2A, CDKN2B, RB1
24	Cell cycle Role of SCF complex in cell cycle regulation⁶⁵ Show member pathways Cell cycle ESR1 regulation of G1/S transition⁶⁵ Cell cycle Regulation of G1/S transition (part 1)⁶⁵ Immune response MIF-JAB1 signaling⁶⁵	8.2	CDK4, CDKN2A, CDKN2B, RB1
25	Cyclins and Cell Cycle Regulation⁵⁸ Show member pathways G1 Phase⁶⁰ G1-S Phase Transition⁵⁸ Cyclin D associated events in G1⁶⁰ Cell Cycle Control by BTG Proteins⁵⁸ Phosphorylation of proteins involved in G1/S transition by active Cyclin E-Cdk2 complexes⁶⁰	8.2	CDK4, CDKN2A, CDKN2B, RB1
26	Viral carcinogenesis³⁴	8.2	CDK4, CDKN2A, CDKN2B, RB1
27	Akt Signaling⁵⁸ Show member pathways p38 Signaling⁵⁸ Tec Kinases Signaling⁵⁸	8.0	CSF3, EPOR, ERBB2, FAS, KIT, KITLG
28	Cell cycle³⁴ ⁴² Show member pathways G1 to S cell cycle control⁴²	7.9	CDK4, CDKN2A, CDKN2B, KITLG, RB1
29	PI3K-Akt signaling pathway³⁴	7.8	CDK4, CSF3, EPO, EPOR, KIT, KITLG
30	Glioma³⁴ Show member pathways Endocrine resistance³⁴ Prostate cancer³⁴ Signaling Pathways in Glioblastoma⁴² Breast cancer³⁴ Melanoma³⁴ Non-small cell lung cancer³⁴ EGFR tyrosine kinase inhibitor resistance³⁴ Estrogen signaling pathway³⁴	7.6	CDK4, CDKN2A, CDKN2B, ERBB2, MTOR, RB1
31	PEDF Induced Signaling⁵⁸ Show member pathways Glucocorticoid Receptor Signaling⁵⁸ Cytokine-cytokine receptor interaction³⁴ Endothelin-1 Signaling Pathway⁵⁸ STAT3 Pathway⁵⁸ IL-6 Pathway⁵⁸ PGC1Alpha Pathway⁵⁸ NFAT Signaling and Lymphocyte Interactions⁵⁸ MIF Regulation of Innate Immune Cells⁵⁸ MIF Mediated Glucocorticoid Regulation⁵⁸ RAR-Gamma-RXR-Alpha Degradation⁵⁸ all-trans-Retinoic Acid Signaling in Brain⁵⁸	7.5	CSF3, EPO, EPOR, ERBB2, FAS, KIT
32	Cellular Senescence⁶⁰ Show member pathways Cellular responses to stress⁶⁰ Oxidative Stress Induced Senescence⁶⁰ Senescence-Associated Secretory Phenotype (SASP)⁶⁰	7.4	CDK4, CDKN2A, CDKN2B, EPO, MTOR, RB1
33	GPCR Pathway⁵⁸ Show member pathways Estrogen Pathway⁵⁸ P2Y Receptor Signaling⁵⁸ Breast Cancer Regulation by Stathmin1⁵⁸ Ras Pathway⁵⁸ Pancreatic Adenocarcinoma⁵⁸ NFAT in Immune Response⁵⁸ Paxillin Interactions⁵⁸	6.8	CDK4, CDKN2A, CDKN2B, EPOR, ERBB2, KIT
34	Pathways in cancer³⁴	6.6	CDK4, CDKN2A, CDKN2B, ERBB2, FAS, KIT
35	ERK Signaling⁵⁸ Show member pathways ILK Signaling⁵⁸ Molecular Mechanisms of Cancer⁵⁸ MAPK Signaling⁵⁸ Rho Family GTPases⁵⁸	5.7	CDK4, CDKN2A, CDKN2B, CSF3, EPOR, ERBB2

GO Terms for genes affiliated with Ewing's Family of Tumors

Sources:
¹⁹Gene Ontology
See all MalaCards sources

Biological processes related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

(show all 22)

id	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription from RNA polymerase III promoter	GO:0045945	10.6	ERBB2, MTOR
2	megakaryocyte development	GO:0035855	10.6	FLI1, KIT
3	ectopic germ cell programmed cell death	GO:0035234	10.6	KIT, KITLG
4	embryonic hemopoiesis	GO:0035162	10.6	KIT, KITLG
5	positive regulation of Ras protein signal transduction	GO:0046579	10.5	EPO, KITLG
6	erythropoietin-mediated signaling pathway	GO:0038162	10.5	EPOR, KIT
7	response to hyperoxia	GO:0055093	10.4	CDK4, EPO
8	positive regulation of tyrosine phosphorylation of Stat5 protein	GO:0042523	10.4	EPO, KIT
9	phosphatidylinositol phosphorylation	GO:0046854	10.3	ERBB2, KIT, KITLG
10	positive regulation of translation	GO:0045727	10.3	CDK4, ERBB2, MTOR
11	positive regulation of MAP kinase activity	GO:0043406	10.3	ERBB2, KIT, KITLG
12	regulation of phosphatidylinositol 3-kinase signaling	GO:0014066	10.3	ERBB2, KIT, KITLG
13	positive regulation of peptidyl-tyrosine phosphorylation	GO:0050731	10.1	CSF3, KITLG, MTOR
14	hepatocyte apoptotic process	GO:0097284	10.1	FAS, RB1
15	negative regulation of phosphorylation	GO:0042326	10.1	CDKN2A, CDKN2B
16	positive regulation of neuron projection development	GO:0010976	10.1	EPO, EPOR, MTOR
17	phosphatidylinositol-mediated signaling	GO:0048015	10.0	ERBB2, KIT, KITLG, MTOR
18	negative regulation of G1/S transition of mitotic cell cycle	GO:2000134	9.9	CDKN2B, RB1
19	G1/S transition of mitotic cell cycle	GO:0000082	9.5	CDK4, CDKN2A, RB1
20	cell cycle arrest	GO:0007050	9.0	CDKN2A, CDKN2B, MTOR, RB1
21	positive regulation of cell proliferation	GO:0008284	8.9	CDK4, CSF3, EPO, EPOR, KIT, KITLG
22	signal transduction	GO:0007165	7.7	CDK4, EPO, EPOR, ERBB2, FAS, KIT

Molecular functions related to Ewing's Family of Tumors according to GeneCards Suite gene sharing:

id	Name	GO ID	Score	Top Affiliating Genes
1	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	GO:0046934	10.3	ERBB2, KIT, KITLG
2	cyclin-dependent protein serine/threonine kinase inhibitor activity	GO:0004861	10.2	CDKN2A, CDKN2B
3	Ras guanyl-nucleotide exchange factor activity	GO:0005088	9.5	ERBB2, KIT, KITLG
4	identical protein binding	GO:0042802	9.2	EPOR, ERBB2, EWSR1, FAS, RB1
5	protein binding	GO:0005515	5.8	CDK4, CDKN2A, CDKN2B, EPO, EPOR, ERBB2